L3VLUP
ProSign in

RLAY · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RLAYAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RLAY
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterRLAYAMGN
Q3 20202 holders, $57m16 holders, $16.3bn
Q4 20204 holders, $23m19 holders, $14.0bn
Q1 20213 holders, $21m16 holders, $14.5bn
Q2 20212 holders, $18m23 holders, $13.8bn
Q3 20214 holders, $449m24 holders, $11.6bn
Q4 20214 holders, $515m21 holders, $10.4bn
Q1 20225 holders, $514m23 holders, $9.9bn
Q2 20224 holders, $16m28 holders, $9.7bn
Q3 20227 holders, $131m21 holders, $7.9bn
Q4 20223 holders, $16m24 holders, $9.3bn
Q1 20234 holders, $129m22 holders, $8.4bn
Q2 20233 holders, $8.6m26 holders, $7.4bn
Q3 20234 holders, $6.9m26 holders, $8.7bn
Q4 20234 holders, $12m24 holders, $8.4bn
Q1 20244 holders, $7.6m25 holders, $6.7bn
Q2 20244 holders, $5.8m20 holders, $8.0bn
Q3 20242 holders, $2.9m21 holders, $8.8bn
Q4 20241 holders, $447k20 holders, $8.2bn
Q1 20251 holders, $28m25 holders, $12.0bn
Q2 20251 holders, $47m20 holders, $10.2bn
Q3 20251 holders, $77m17 holders, $10.4bn
Q4 20253 holders, $127m19 holders, $18.0bn
Q1 2026none listed holders, n.a.15 holders, $21.4bn
Q2 20262 holders, $25m23 holders, $24.9bn
RLAY

Relay Therapeutics Inc

Holders
1
Reported value
$47m
Buyers
1
Sellers
0

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
20
Reported value
$10.2bn
Buyers
13
Sellers
8

Breadth +5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 21 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only RLAY (1)

Point72 Asset Management LP

Only AMGN (20)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →